EUCTR2004-001773-26-IT进行中（未招募）不适用
A phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BAYER
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinomaEUCTR2004-001773-26-DEBayer HealthCare AG, D-51368 Leverkusen Germany560
进行中（未招募）
不适用
A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma** Amendment 1 Version 2.0 of December 13th 2004 is also includedAdvanced hepatocellular carcinomaMedDRA version: 7.1Level: LLTClassification code 10049010EUCTR2004-001773-26-BEBayer HealthCare AG560
已完成
3 期
A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinomaAdvanced hepatocellular carcinoma.Cancer - LiverACTRN12605000644662Bayer Australia Ltd602
进行中（未招募）
1 期
A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinomaAdvanced hepatocellular carcinomaMedDRA version: 7.1 Level: LLT Classification code 10049010EUCTR2004-001773-26-ESBayer HealthCare AG, D-51368 Leverkusen Germany
进行中（未招募）
3 期
Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in endometrial cancerEndometrial CancerJPRN-jRCT2031210512Fujiwara Keiichi60